Shuhui Yu

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Li Yang, Li Yang, He Huang, 2021, Clinical Cancer Research.

G9a Regulates Cell Sensitivity to Radiotherapy via Histone H3 Lysine 9 Trimethylation and CCDC8 in Lung Cancer

Xiaoling Liu, Zhengting Chen, Ke Cao, 2021, OncoTargets and therapy.

Hepatitis B or C viral infection and the risk of cervical cancer

Jinping Zhang, Xing-rao Wu, Shuhui Yu, 2022, Infectious Agents and Cancer.

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

He Huang, G. Wei, Q. Mu, 2022, Cell Research.

MiR-4429 Alleviates Malignant Behaviors of Lung Adenocarcioma Through Wnt/β-Catenin Pathway.

Qin Shen, Ya Li, Shuhui Yu, 2021, Cancer biotherapy & radiopharmaceuticals.

Targeting eradication of malignant cells derived from human bone marrow mesenchymal stromal cells.

K. Sung, Jun Du, Li Yang, 2010, Experimental cell research.